BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Novartis Europharm Ltd submitted on 28 April 2004 an application for Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Aclasta, 
through the centralised procedure. After agreement by the CHMP on 25 November 2003, this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Dr Per Nilsson 
Scientific Advice: 
Co-Rapporteur: 
Prof Magnus Johannsson 
The applicant received Scientific Advice from the CHMP on 16 November 2001, 27 January 2003 and 
26 March 2004. The Scientific Advice pertained to clinical and non-clinical aspects of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
•  The application was received by the EMEA on 28 April 2004.  
•  The procedure started on 17 May 2004. 
•  The Rapporteur's first Assessment Report was circulated to all CHMP members on 23 July 2004. 
The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  22  July 
2004. 
•  During  the  meeting  on  13-16  September  2004,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the 
applicant on 15 September 2004. 
•  The applicant submitted the responses to the CHMP consolidated List of Questions on 8 November 
2004. 
•  The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of 
Questions to all CHMP members on 16 December 2004. 
•  The Rapporteurs’ Final Recommendation was circulated to the CHMP on 13 January 2005. 
•  During the meeting on 17-20 January 2005, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Aclasta  on  20  January  2005.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 19 January 2005. 
•  The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 15 April 2005. 
1/1 

EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
